| 转移性肾细胞癌的靶向治疗研究进展 |
| |
| 引用本文： | 杜贤进. 转移性肾细胞癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2009, 36(7). DOI: 10.3760/cma.J.jssn.1673-422X.2009.07.018 |
| |
| 作者姓名： | 杜贤进 |
| |
| 作者单位： | 武汉大学人民医院泌尿外科,430060 |
| |
| 摘 要： | 转移性肾细胞癌靶向治疗的药物包括VHL-低氧缺乏因子-血管内皮生长因子(VHL-HIF-VEGF)途径靶向药物舒尼替尼、索拉非尼、贝伐单抗、阿西替尼等和哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂西罗莫司脂化物、依维莫司等.这些靶向药物在转移性肾细胞癌的治疗中取得了良好的效果,但是其不良反应需要引起足够的重视.在患者治疗方案上的选择以及对非透明肾细胞癌的治疗效果方面还需要进一步的研究.
|
| 关 键 词： | 肾肿瘤 靶向药物 |
Target therapy in metastatic renal cell carcinoma |
| |
| DU Xian-jin. Target therapy in metastatic renal cell carcinoma[J]. Journal of International Oncology, 2009, 36(7). DOI: 10.3760/cma.J.jssn.1673-422X.2009.07.018 |
| |
| Authors: | DU Xian-jin |
| |
| Abstract: | The targeted agents of metastatic renal cell carcinoma include the inhibitor of the VHL- HIF-VEGF pathway(sunitinib、 sorafenib、 bevacizumab、 Axitinib) and the mTOR pathway (Temsirolimus, Everoli-mus). These targeted chugs suggest the onset of a new therapeutic era for patients with metastatic renal cell car-cinoma. It is necessary to pay more attention to the side effect. The therapeutic scheme choice of patients and the treatment effect of the non-clear cell carcinomal need further studies. |
| |
| Keywords: | Kidney neoplasms Targeted agents |
| 本文献已被 万方数据 等数据库收录！ |
